These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Weapons of mass protection. Nat Med; 2003 Mar; 9(3):239. PubMed ID: 12612548 [No Abstract] [Full Text] [Related]
4. Medicine. The intangible value of vaccination. Rappuoli R; Miller HI; Falkow S Science; 2002 Aug; 297(5583):937-9. PubMed ID: 12169712 [No Abstract] [Full Text] [Related]
5. The U.S. vaccine supply. Hinman AR N Engl J Med; 2005 Mar; 352(10):1046-7; author reply 1046-7. PubMed ID: 15758020 [No Abstract] [Full Text] [Related]
6. Vaccine venture boosts health hopes. Butler D Nature; 2009 Sep; 461(7262):323. PubMed ID: 19759588 [No Abstract] [Full Text] [Related]
7. Policy analysis: an essential research tool for the introduction of vaccines in developing countries. Mahoney R J Health Popul Nutr; 2004 Sep; 22(3):331-7. PubMed ID: 15609786 [TBL] [Abstract][Full Text] [Related]
8. India: 50 years after independence. Miller DD; Nayak AR Nat Biotechnol; 1997 Aug; 15(8):727-9. PubMed ID: 9255782 [No Abstract] [Full Text] [Related]
9. Paving the way for the introduction of new vaccines into developing countries. Chabalgoity JA Expert Rev Vaccines; 2005 Apr; 4(2):147-50. PubMed ID: 15889986 [TBL] [Abstract][Full Text] [Related]
10. Introducing new vaccines into developing countries: obstacles, opportunities and complexities. Clemens J; Jodar L Nat Med; 2005 Apr; 11(4 Suppl):S12-5. PubMed ID: 15812482 [TBL] [Abstract][Full Text] [Related]
12. Drug and vaccine development for infectious diseases: the value of priority review vouchers. Matheny J; Smith B; Courtney B; Mair M Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907 [No Abstract] [Full Text] [Related]
13. The fight to manufacture COVID vaccines in lower-income countries. Maxmen A Nature; 2021 Sep; 597(7877):455-457. PubMed ID: 34526695 [No Abstract] [Full Text] [Related]
14. Indian biotechnology--rapidly evolving and industry led. Kumar NK; Quach U; Thorsteinsdóttir H; Somsekhar H; Daar AS; Singer PA Nat Biotechnol; 2004 Dec; 22 Suppl():DC31-6. PubMed ID: 15583682 [No Abstract] [Full Text] [Related]
15. New technology, old struggles plague vaccine developers. Phillips L Hosp Technol Ser; 1994 Oct; 13(13):3-6. PubMed ID: 10137963 [No Abstract] [Full Text] [Related]
16. The impact of globalization on vaccine development and availability. Milstien JB; Kaddar M; Kieny MP Health Aff (Millwood); 2006; 25(4):1061-9. PubMed ID: 16835187 [TBL] [Abstract][Full Text] [Related]
17. The winning shot. New vaccine technologies to offer pinpoint attacks on a variety of potentially deadly diseases. Kirchheimer B Mod Healthc; 2005 Nov; 35(46):52-4. PubMed ID: 16334833 [No Abstract] [Full Text] [Related]
18. [Relationship between pharmaceutical industry and public health in vaccination]. Gervasi G; Capanna A; Soncini R; Zaratti L; Franco E Ig Sanita Pubbl; 2015; 71(2):225-32. PubMed ID: 26057178 [TBL] [Abstract][Full Text] [Related]
19. Brazil and India access pharma vaccine know-how. Neto RB; Jayaraman K Nat Biotechnol; 2009 Dec; 27(12):1063-4. PubMed ID: 20010560 [No Abstract] [Full Text] [Related]
20. Oral vaccines: new needs, new possibilities. Aziz MA; Midha S; Waheed SM; Bhatnagar R Bioessays; 2007 Jun; 29(6):591-604. PubMed ID: 17508389 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]